2. Search Result
Search Result
Results for "

CDK6-IN-1

" in MedChemExpress (MCE) Product Catalog:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-16297
    Abemaciclib methanesulfonate
    115+ Cited Publications

    LY2835219 methanesulfonate

    		 CDK Cancer
    Abemaciclib methanesulfonate (LY2835219 methanesulfonate) is a selective and BBB-permeable CDK4/6 inhibitor with IC50s of 2 nM and 10 nM for CDK4 and CDK6, respectively .
    Abemaciclib methanesulfonate
  • HY-136250
    BSJ-03-204

    		PROTACs CDK Cancer
    BSJ-03-204 is a PROTAC connected by ligands for Cereblon and CDK. BSJ-03-204 is a potent and selective Palbociclib-based CDK4/6 dual degrader (PROTAC), with IC50s of 26.9 nM and 10.4 nM for CDK4/D1 and CDK6/D1, respectively. BSJ-03-204 does not induce IKZF1/3 degradation and has anti-cancer activity .
    BSJ-03-204
  • HY-136252
    BSJ-04-132

    		PROTACs CDK Cancer
    BSJ-04-132 is a PROTAC connected by ligands for Cereblon and CDK. BSJ-04-132 is a potent and selective Ribociclib-based CDK4 degrader (PROTAC), with IC50s of 50.6 nM and 30 nM for CDK4/D1 and CDK6/D1, respectively. BSJ-04-132 does not induce CDK6 and IKZF1/3 degradation. BSJ-04-132 has anti-cancer activity .
    BSJ-04-132
  • HY-168620
    CDK6-IN-1

    		CDK Cancer
    CDK6-IN-1 (compound 4i) is a CDK6 inhibitor. CDK6-IN-1 inhibits cell growth and induces cell cycle arrest at G1-phase .
    CDK6-IN-1
  • HY-114339
    CDK4/6-IN-2

    		CDK Cancer
    CDK4/6-IN-2 is a potent CDK4 and CDK6 inhibitor extracted from patent US20180000819A1, Compound 1, has IC50s of 2.7 and 16 nM for CDK4 and CDK6, respectively .
    CDK4/6-IN-2
  • HY-142696A
    CDK6/PIM1-IN-1 hydrochloride

    		CDK Pim Apoptosis Cancer
    CDK6/PIM1-IN-1 (Compound 51) hydrochloride is an orally active and potent dual CDK6/PIM1 inhibitor with IC50 values of 39 and 88 nM, respectively. CDK6/PIM1-IN-1 hydrochloride inhibits CDK4 (IC50=3.6 nM). CDK6/PIM1-IN-1 hydrochloride significantly inhibits acute myeloid leukemia (AML) cell proliferation, arrest cell cycle at the G1 phase, and promote cell apoptosis. CDK6/PIM1-IN-1 exhibits potent anti-AML activity .
    CDK6/PIM1-IN-1 hydrochloride
  • HY-136250A
    BSJ-03-204 triTFA

    		PROTACs CDK Cancer
    BSJ-03-204 triTFA is a PROTAC connected by ligands for Cereblon and CDK. BSJ-03-204 triTFA is a potent and selective Palbociclib-based CDK4/6 dual degrader (PROTAC), with IC50s of 26.9 nM and 10.4 nM for CDK4/D1 and CDK6/D1, respectively. BSJ-03-204 triTFA does not induce IKZF1/3 degradation and has anti-cancer activity .
    BSJ-03-204 triTFA
  • HY-142696
    CDK6/PIM1-IN-1

    		CDK Pim Apoptosis Cancer
    CDK6/PIM1-IN-1 is a potent and balanced dual CDK6/PIM1 inhibitor with IC50 values of 39 and 88 nM, respectively. CDK6/PIM1-IN-1 inhibits CDK4 (IC50=3.6 nM). CDK6/PIM1-IN-1 significantly inhibits acute myeloid leukemia (AML) cell proliferation, arrest cell cycle at the G1 phase, and promote cell apoptosis. CDK6/PIM1-IN-1 exhibits potent anti-AML activity .
    CDK6/PIM1-IN-1
  • HY-16297R
    Abemaciclib methanesulfonate (Standard)

    LY2835219 methanesulfonate (Standard)

    		 Reference Standards CDK Cancer
    Abemaciclib (methanesulfonate) (Standard) is the analytical standard of Abemaciclib (methanesulfonate). This product is intended for research and analytical applications. Abemaciclib methanesulfonate (LY2835219 methanesulfonate) is a selective CDK4/6 inhibitor with IC50s of 2 nM and 10 nM for CDK4 and CDK6, respectively .
    Abemaciclib methanesulfonate (Standard)
  • HY-179452
    KRAS G13D-IN-2

    		Ras CDK Mitochondrial Metabolism Cancer
    KRAS G13D-IN-2 (compound 8B) is a potent orally active KRAS G13D inhibitor with IC50 values of 1.95 μM (HCT-116 G13D) and 2.16 μM (HCT-15 G13D). KRAS G13D-IN-2 induces G1-phase arrest and mitochondrial membrane depolarization. KRAS G13D-IN-2 induces senescence through CDK6/TWIST1 inhibition. KRAS G13D-IN-2 inhibits tumor growth in murine models. KRAS G13D-IN-2 can be used for KRAS G13D-mutant colorectal cancer research .
    KRAS G13D-IN-2
  • HY-E70686
    CDK6/CycD1 Recombinant Human Active Protein Kinase

    		CDK Cancer
    CDK6 is a cell-cycle kinases that regulate exit from the G1 phase of the cell cycle. CDK6 is directly involved in transcription in tumor cells and in hematopoietic stem cells. CDK6/CycD1 Recombinant Human Active Protein Kinase is an ortholog of CDK6 .
    CDK6/CycD1 Recombinant Human Active Protein Kinase
  • HY-101467AR
    Trilaciclib hydrochloride (Standard)

    G1T28 hydrochloride (Standard)

    		 Reference Standards CDK Cancer
    Trilaciclib (hydrochloride) (Standard) is the analytical standard of Trilaciclib (hydrochloride). This product is intended for research and analytical applications. Trilaciclib hydrochloride (G1T28 hydrochloride) is a CDK4/6 inhibitor with IC50s of 1 nM and 4 nM for CDK4 and CDK6, respectively .
    Trilaciclib hydrochloride (Standard)
  • HY-115942
    Anticancer agent 29

    		CDK Cancer
    Anticancer agent 29 (Compd E/Z-6f) is an anticancer agent, with IC50 values of 0.054 μM, 0.127 μM, 0.129 μM, 0.396 μM for CDK2, CDK1, CDK4 and CDK6, respectively .
    Anticancer agent 29
  • HY-180277
    PROTAC CDK6 Degrader 1

    		PROTACs CDK Apoptosis Cancer
    PROTAC CDK6 Degrader 1 (compound 48a) is a potent and selective PROTAC CDK6 degrader with a DC50 of 0.037 μM. PROTAC CDK6 Degrader 1 exhibits selectivity over CDK4 (DC50 > 10 μM). PROTAC CDK6 Degrader 1 induces G0/G1 cell-cycle arrest and apoptosis through inhibition of CDK6 downstream signaling. PROTAC CDK6 Degrader 1 reduces tumor burden and CDK6 levels in a MOLM-14 xenograft mouse model. PROTAC CDK6 Degrader 1 can be used for CDK6-driven cancers research, such as acute myeloid leukemia (AML) .
    PROTAC CDK6 Degrader 1
  • HY-180280
    KLHDC2 ligand 3

    		Ligands for E3 Ligase Cancer
    KLHDC2 ligand 3 is an E3 ligase ligand. KLHDC2 ligand 3 can be used for the synthesis of PROTAC CDK6 Degrader 1 (HY-180277) .
    KLHDC2 ligand 3
  • HY-180278
    PROTAC CDK6 ligand 2

    		CDK Cancer
    PROTAC CDK6 ligand 2 is a ligand for target CDK6 protein for PROTAC. PROTAC CDK6 ligand 2 can be used for the synthesis of PROTAC CDK6 Degrader 1 (HY-180277) .
    PROTAC CDK6 ligand 2
  • HY-180279
    CDK6 ligand-Linker Conjugate 1

    		Target Protein Ligand-Linker Conjugates CDK Cancer
    CDK6 ligand-Linker Conjugate 1 is a target protein ligand-linker conjugate that incorporates a ligand for CDK6 (HY-180278) and a linker, which recruits E3 ligases. CDK6 ligand-Linker Conjugate 1 can be used for synthesis of PROTAC CDK6 Degrader 1 (HY-180277) .
    CDK6 ligand-Linker Conjugate 1
  • HY-180262
    PROTAC CDK6 Degrader 2

    		PROTACs CDK Cancer
    PROTAC CDK6 Degrader 2 (compound 48b), the active form of PROTAC CDK6 Degrader 1 (HY-180277), is a potent and selective PROTAC CDK6 degrader that binds strongly to KLHDC2 (KD = 0.005 μM). PROTAC CDK6 Degrader 2 functions through a KLHDC2-dependent and ubiquitin-proteasome-mediated mechanism. PROTAC CDK6 Degrader 2 can be used for cancer research .
    PROTAC CDK6 Degrader 2
  • HY-180817
    CDK2-IN-55

    		CDK Aurora Kinase Apoptosis Cancer
    CDK2-IN-55 (Compound 12c) is a CDK2 inhibitor with an IC50 value of 4.7 nM. CDK2-IN-55 also has a strong inhibitory effect on CDK1 (IC50 = 26.3 nM), moderate inhibitory effects on Aurora A (IC50 = 92.0 nM) and CDK9 (IC50 = 288 nM), and very weak inhibitory activities on CDK4, CDK6, DYRK1A, and GSK3β (IC50 > 1000 nM). CDK2-IN-55 shows strong anti-proliferative activity against various cancer cell lines, inducing cell cycle arrest and apoptosis. CDK2-IN-55 can be used for research on colorectal cancer, lung cancer, and cervical cancer .
    CDK2-IN-55

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: